Health Care·Biotechnology·$2.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.42 | N/A | +24.99% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.42 | N/A | +24.99% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about market conditions affecting performance. They remain focused on their strategic initiatives.
Management highlighted ongoing challenges in the current market environment.
They emphasized the importance of focusing on long-term goals despite short-term setbacks.
Sarepta Therapeutics reported a wider-than-expected loss per share, which was a positive surprise compared to previous expectations. However, the lack of revenue data and no guidance for future performance led to a 4.44% decline in the stock price. Investors may be cautious as the company navigates ongoing market challenges.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WASTE MGMT INC DEL
Nov 2, 2020